- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.10. | Kyverna links CAR-T to improved autoimmune outcomes in small trial | ||
| 29.10. | GSK abandons hopes for CD226 cancer therapies, dropping remaining phase 2 assets | ||
| 28.10. | Eli Lilly and Nvidia team up to build 'most powerful' supercomputer in pharma | ||
| 28.10. | Edesa claims survival data win for phase 3 respiratory failure trial | ||
| 28.10. | Aldeyra shuffles RASP pack, dropping and swapping assets in response to data | ||
| 28.10. | Incyte scraps BET inhibitor against backdrop of safety concerns for the drug class | ||
| 28.10. | GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides | ||
| 27.10. | 2025 M&A up in value and deal count after year of 'conservatism and recovery': Leerink Partners | ||
| 27.10. | Intellia pauses phase 3 CRISPR trials after patient is hospitalized | ||
| 27.10. | Zenas' lead autoimmune drug prompts 95% reduction in new brain lesions in phase 2 MS study | ||
| 27.10. | BridgeBio aces phase 3 rare disease test, clearing path to FDA | ||
| 27.10. | MapLight goes public via $250M IPO to fund Cobenfy competitor | ||
| 27.10. | GSK pens $357M pact with French biotech for preclinical prostate cancer ADC | ||
| 24.10. | Eli Lilly buys cash-strapped Adverum for its phase 3-stage eye disease gene therapy | ||
| 24.10. | Biogen beefs up immunology pipeline with $1B deal for Vanqua's preclinical C5aR1 antagonist | ||
| 24.10. | Sanofi drops RSV vaccine for toddlers after phase 3 trial heads for failure | ||
| 23.10. | Regeneron does 180 on 2seventy lymphoma CAR-T, halting study and nixing further development | ||
| 23.10. | Ventyx's CV drug reduces cardio risk biomarker by nearly 80% in 1st week of phase 2 study | ||
| 23.10. | Roche axes 4 Chugai solid tumor assets in early-phase clearout | ||
| 22.10. | Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3 | ||
| 22.10. | Arcturus' stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial | ||
| 22.10. | Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial | ||
| 22.10. | Sanofi's $1.7B rare disease bet beats CSL's Zemaira in phase 2 face-off | ||
| 22.10. | Ipsen writes check worth up to €1B to acquire next-gen cancer biotech | ||
| 22.10. | Takeda pays Innovent $1.2B upfront for rights to 2 cancer candidates |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .